Home > Boards > US OTC > Miscellaneous >

SentiSearch, Inc. (SSRC)

SSRC RSS Feed
Add SSRC Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/5/2020 8:41:50 PM - Followers: 8 - Board type: Free - Posts Today: 0

SentiSearch, Inc.
27 East 62nd St, Suite 9D
New York, NY 10065
Phone: 561-653-3284
www.sentisearch.com
Authorized shares: 40,000,000 common, no preferred authorized
Outstanding shares: As of August 10, 2011, the Company had outstanding 16,821,787 shares of Common Stock. (from 10q filed 8/15/11)
75.5% beneficially held http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62366033

From 10q filed 8/15/11: Primarily due to the estimated revenues to be earned under the Development Agreement described below under the heading "Development Agreement", entered into on August 31, 2010, management has determined that the Company has commenced its planned principal operations and was no longer considered a development stage company as of September 15, 2010.

 
About SentiSearch
SentiSearch, Inc. holds certain olfaction intellectual property assets primarily consisting of an exclusive world wide license issued by the Trustees of Columbia University in the City of New York, as well as certain patent applications. SentiSearch has been working with Professor Axel and his team in the area of olfaction and has also been in contact at various times in this period with leading scientists at Rockefeller University. These efforts resulted in the collaborative agreement with Bayer CropScience AG in September 2010.
__________________________________________________________________________________________________________________________________________________________________________________________________

From the 2010 Bayer annual report, page 43. One of only 16 stories presented as "Highlights 2010." smile

http://www.annualreport2010.bayer.com/en/bayer-annual-report-2010.pdfx

Grabbing Malaria Mosquitoes "By the Nose"

New approaches to fighting malaria:
Bayer CropScience and SentiSearch Inc. plan to work together with leading U.S.-based scientists to "grab insects by the nose." The two companies have entered into a two-year research collaboration aimed at identifying new molecules to target odorant receptors in insects. Such substances could prevent disease transmitting insects from being able to "smell" people. Millions of olfactory receptor neurons help the insects not only to locate food, but also to home in on a host where they can lay their eggs. These insects are more than just bothersome to people: they can also be very dangerous. One example is the malaria-transmitting Anopheles mosquito, which identifies its hosts partly by the co2 content of their breath. The aim is for the new molecules to block the relevant receptors so that the insects can no longer perceive human odors. "Bayer CropScience is the market leader in vector control in the public health and agricultural settings, including animal health. Our activities include playing a significant role in the prevention of malaria," said Dr. Alexander Klausener, Head of Research at Bayer CropScience. According to Klausener, this new cooperation with leading scientists from Columbia and The Rockefeller University in New York will give the company access to a new and innovative approach to insect control.

__________________________________________________________________________________________________________________________________________________________________________________________________

Latest News
From the New York Times, published 12/21/10:

Five Years In, Gauging Impact of Gates Grants
SEATTLE - Five years ago, Bill Gates made an extraordinary offer: he invited the world's scientists to submit ideas for tackling the biggest problems in global health, including the lack of vaccines for AIDS and malaria, the fact that most vaccines must be kept refrigerated and be delivered by needles, the fact that many tropical crops like cassavas and bananas had little nutrition, and so on.
About 1,600 proposals came in, and the top 43 were so promising that the Bill & Melinda Gates Foundation made $450 million in five-year grants - more than double what he originally planned to give.
...Mosquito 'Olfacticides'
As the inventors of "a cell line that behaves like a mosquito antenna, recreating mosquito smellers in a dish," Leslie B. Vosshall of Rockefeller University and Dr. Richard Axel, a Howard Hughes Medical Institute investigator at Columbia University, got $5 million to hunt for molecules that could block mosquitoes' ability to detect people. Dr. Axel shared a 2004 Nobel Prize in Medicine for cloning insects' olfactory receptors.
"When you puff human odors over the cells, they get excited just like mosquitoes would," Dr. Vosshall explained. In this case, they turn fluorescent green.
They tested 91,000 compounds in Rockefeller University's chemical library and found five that jammed the antennae. Their Gates grant is renewed for two years, but they now have a contract with Bayer CropSciences to screen its two million compounds - the same smell mechanism is used by corn borers, apple maggot flies and other farm pests. (my emphasis, link to details of the 2 year SSRC agreement with Bayer below.)
The ideal, Dr. Axel said, is a repellent harmless to humans that works at a fraction of the concentration of DEET..."

the whole article

http://www.nytimes.com/2010/12/21/health/21gates.html?pagewanted=1&_r=2&hp

SSRC'S agreement with Bayer Crop Science
http://www.docstoc.com/docs/61922062/Research-And-Product-Development-Agreement-Project-Research-And-Product-Development-Agreement---SENTISEARCH----11-15-2010

From the last SSRC 10k:
"We believe the applications offering the greatest potential for developing products in the intermediate term are for mosquito repellants to be sold by household product companies
"

Bayer CropScience, SentiSearch and Leading US Universities Enter Research Cooperation

PR Newswire    "Press Releases US - English "

MONHEIM, Germany and WEST PALM BEACH, Fla., Nov. 1, 2010 /PRNewswire/ -- Bayer CropScience and SentiSearch, Inc. (OTC Bulletin Board: SSRC) have entered into a two-year research agreement to cooperate in the identification of new molecules targeting odorant receptors in insects. The aim of this collaboration, which also involves arrangements with Columbia University and Rockefeller University, is to develop innovative solutions to improve control of malaria and dengue fever in countries where these diseases are endemic. SentiSearch will receive an upfront license fee, followed by milestone payments and royalties on sales. Further financial terms were not disclosed.
Bayer CropScience will contribute to this project its extensive library of compounds, screening capabilities and its experience in chemical synthesis and the development of insecticides. In turn, SentiSearch and the Universities will together provide proprietary assay technologies and knowledge in the field of chemoreception in insects. This will enable Bayer CropScience to use these assays to identify compounds which could modify the activity of insect odor receptors. In addition to possible benefits in the field of public health, these activities could also result in innovative products with a new mode of action capable of preventing damage to agricultural crops caused by insects. Bayer CropScience will determine whether compounds successfully identified will be developed for agricultural applications.
This project will build on the groundbreaking research carried out by Drs. Richard Axel and Leslie Vosshall, who discovered chemosensory receptors that are responsible for odor perception. Various insect behaviors are guided by the sense of smell, including the ability to locate food, humans, animals, and mating partners. Mosquitoes, which transmit dangerous tropical diseases to humans, use the CO2 content of exhaled air and other host odors to locate their hosts. The aim is for the new molecules to block the relevant receptors, which would prevent the insect from perceiving human odors. Receptors have also been discovered that are responsible for male courtship behavior and for guiding the deposition of eggs by female insects on their host plants. Professor Axel was awarded the 2004 Nobel Prize in Physiology or Medicine for his groundbreaking studies on olfactory perception.
"Bayer CropScience is the market leader in vector control in the public health and agricultural settings, including animal health," said Dr. Alexander Klausener, Head of Research at Bayer CropScience. "Our activities include playing a significant role in the prevention of malaria. This new cooperation with leading U.S. scientists Nobel Laureate Professor Richard Axel from Columbia University and Professor Leslie Vosshall from Rockefeller University will give us access to a new and innovative approach to insect control. This, in turn, will present us with an opportunity to expand our leading position in this field."
"Through this agreement, we have brought together united leading researchers around a mission: to control the spread of malaria and other insect-borne diseases around the world. It is our further belief that this initiative may yield additional significant opportunities in health and agriculture," commented Joseph K. Pagano, Chief Executive Officer at SentiSearch. "We are pleased to be working with Bayer CropScience and the superb scientists who have been involved at Columbia and Rockefeller Universities," added Mr. Pagano.
This collaboration is part of a research project performed in Professor Axels laboratory at Columbia University and in Professor Vosshall's laboratory at Rockefeller University. The project funded by a Grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative. One of the goals of that initiative is to improve the control of insects that affect human health, with the ultimate eradication of malaria, dengue fever, and other insect-borne diseases in the developing world.

About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.5 billion (2009), is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 18,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.

Find more information at www.bayercropscience.com.
Kgs (2010-0489E)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

SentiSearch, Inc.: This Release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements using terminology such as "can", "may", "believe", "designed to", "intend to", "expect", "plan", "anticipate", "estimate", "potential" or "continue", or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition, and state other "forward-looking" information. We believe it is important to communicate our expectations. However, forward-looking statements involve risks and uncertainties and our actual results and the timing of certain events could differ materially from those discussed in or implied by forward-looking statements as a result of certain factors, including those set forth under "Management's Discussion and Analysis and Results of Operations" and elsewhere in the Company's Annual Report on Form 10-K. All forward-looking statements included in this Release are made as of the date hereof, based on information available to us as of the date thereof, and we assume no obligations to update any forward-looking statement, unless we are required to do so by law.
SOURCE SentiSearch, Inc.

8k filed 9/1/10:

"ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On August 31, 2010, SentiSearch, Inc. (the "Company") entered into a Project Research and Product Development Agreement (the "Agreement") with Bayer CropScience AG ("Bayer"), effective September 15, 2010, pursuant to which the Company and Bayer will cooperate in the identification and development of molecules affecting olfaction (the sense of smell) in insects. This approach is designed to exploit advances in neuroscience to safely and effectively prevent crop damage and the spread of human disease by altering insect behavior. This approach may allow for a new level of specificity and efficiency of insect control.

Under the Agreement, the Company will provide to Bayer proprietary technology for screening particular compounds in Bayer's chemical library that may affect the function of insect odorant receptors. Bayer's efforts will be undertaken as part of a collaborative research project (the "Research Project") with investigators at Columbia and Rockefeller Universities in New York. Support for the Research Project is being provided by a grant award to Columbia from the Foundation for the National Institutes of Health (FNIH) through the Grand Challenges in Global Health initiative (the "Initiative") of the Bill & Melinda Gates Foundation. One of the goals of the Initiative is to improve the control of insects that affect human health, with the ultimate goal of eradication of malaria, Dengue fever and other insect borne diseases in the developing world.

Bayer will determine whether to develop further, for crop control applications, compounds identified in the course of the Research Project.

In connection with the Agreement, the Company has granted to Bayer certain exclusive rights to use its proprietary technology in the field of use of the Agreement (any use against invertebrate animals other than the prevention, diagnosis or treatment of human health conditions). Bayer will provide the Company with the opportunity to acquire a license in the field of use to further develop compounds identified by Bayer in the course of the Research Project, which Bayer determines not to further develop itself. Bayer has also granted the Company an exclusive option, for a period of five years, to negotiate and execute a license from Bayer with respect to compounds identified by Bayer in the course of the Research Project, for use outside the field of use and outside the field of agriculture.

As part of the Agreement, Bayer has paid to the Company an upfront fee and has agreed to pay to the Company additional amounts upon achieving certain milestones and royalties on net sales of products developed pursuant to the project. Consistent with the global access policy of the Grand Challenges program and the award agreement to Columbia University from FNIH, the Agreement also provides for certain guidelines with respect to distribution and pricing of products for those most in need in disease endemic countries.

Forward-Looking Statements
This Current Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements using terminology such as "can", "may", "believe", "designed to", "intend to", "expect", "plan", "anticipate", "estimate", "potential" or "continue", or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition, and state other "forward-looking" information.
We believe it is important to communicate our expectations. However, forward-looking statements involve risks and uncertainties and our actual results and the timing of certain events could differ materially from those discussed in or implied by forward-looking statements as a result of certain factors, including those set forth under "Management's Discussion and Analysis and Results of Operations" and elsewhere in the Company's Annual Report on Form 10-K. All forward-looking statements included in this Current Report are made as of the date hereof, based on information available to us as of the date thereof, and we assume no obligations to update any forward-looking statement, unless we are required to do so by law.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SENTISEARCH, INC.

Dated: September 1, 2010 By: /s/ Joseph K. Pagano
Name: Joseph K. Pagano
Title: Chief Executive Officer, Secretary,
Treasurer and Chairman of the Board
________________________________________________________________________________________________________________________________________________________________________________________________

Company information from www.answers.com:

SentiSearch, Incorporated is a Delaware corporation that was incorporated on October 3, 2006. The Company was previously a wholly-owned subsidiary of Sentigen Holding Corp. (Sentigen) and was incorporated solely for the purposes of holding the olfaction intellectual property assets of Sentigen and its then subsidiary, Sentigen Biosciences, Inc. (Sentigen Biosciences). Prior to the merger between Sentigen and Invitrogen Corporation (Invitrogen) that was consummated on December 1, 2006, Sentigen separated its olfaction intellectual property assets from the businesses to be acquired by Invitrogen. This separation was accomplished through the contribution of Sentigen's olfaction intellectual property assets to the Company on October 10, 2006 and the subsequent spin-off in which Sentigen distributed 100% of its ownership interest in them. As a result of this spin-off, SentiSearch became a public, stand-alone company. The olfaction intellectual property assets that the Company holds mainly consist of an exclusive worldwide license issued by The Trustees of Columbia University in the City of New York, and certain patent applications titled 'Nucleic Acids and Proteins of Insect or 83b odorant receptor genes and uses thereof'. SentiSearch is currently a development stage company and has a limited operating history. SentiSearch faces competition mainly from universities, including Yale University and Vanderbilt University, who are conducting the research and have patent applications pertaining to areas relevant to olfaction technology. In the event SentiSearch is able to commercialize its research and development activities and depending on the development objectives and uses of any of its potential products, the Company might become subject to government regulation by certain government agencies including the Food and Drug Administration and the Environmental Protection Agency.

Info on Mr. Pagano, the CEO, from Forbes:

Joseph K. Pagano has served as our Chief Executive Officer, Secretary and Treasurer and as the Chairman of our Board since our formation in October 2006 and as the Chairman of the Board of Sentigen from 1996 until November 2006. He served as Sentigen?s Chief Executive Officer and President from 1996 through March 21, 2006. Mr. Pagano has been a private investor for more than the past five years. Mr. Pagano has been active in venture capital for over 20 years, with investments in a wide variety of industries, including information and technology, medical equipment, biotechnology, communications, retailing and outsourcing. He was a founding investor in Ribi Immunochem, one of the earliest biotechnology companies to go public and one of the first to focus on cancer vaccines. He participated in the early round financing of Amcell Cellular Communication, which was sold to Comcast. He was a founding investor of NMR of America, the first MRI center business to go public and was also a founding shareholder and director of Office Depot, the first office warehouse to go public.

http://people.forbes.com/profile/joseph-k-pagano/71103


Excerpts from 10K filed 3/31/10:

"On April 10, 2000, Sentigen Biosciences entered into the Columbia License described below. On October 10, 2006, we entered into a contribution agreement with Sentigen pursuant to which Sentigen transferred to us all of its olfaction intellectual property, including the Columbia License. On October 17, 2006, Columbia consented to the assignment of the Columbia License from Sentigen Biosciences to us subject to certain conditions, all of which have been satisfied to the extent currently required.
The Columbia License provides us with worldwide rights to certain of Columbia's patent applications and other rights in the areas of insect chemosensation and olfaction. The Columbia License gives us an exclusive license to develop, manufacture, have made, import, use, sell, distribute, rent or lease (i) any product or service the development, manufacture, use, sale, distribution, rental or lease of which is covered by a claim of a patent licensed to us under the Columbia License or (ii) any product or service that involves the know-how, confidential information and physical materials conveyed by Columbia to us relating to the patents licensed from Columbia (collectively, the "Licensed Products/Services"). In addition to certain funding requirements by Sentigen, all of which were satisfied, in consideration of the Columbia License, Columbia was issued 75,000 shares of Sentigen common stock and will receive royalties of 1% of the net sales of any Licensed Products/Services"
During July 2007, we were issued two patents in the United States and during November 2007, we were issued a patent in Australia and during 2008, we were issued one patent in Mexico. One of the U.S. patents and the Australia and Mexico patents, were issued directly to us and the other U.S. patent was issued under the Columbia License. All of the issued patents cover nucleic acid molecules which encode insect odorant receptor proteins, including numerous variations on insect odorant receptor coding sequence. The patents cover any nucleic acid molecule as long as the protein it encodes contains a short segment of amino acids, linked together.
We believe that our olfaction intellectual property may be of value to commercial and non-profit partners wishing to develop novel, safer and more effective means to control pest insects through molecular manipulation of insect olfaction and taste. This effort would aim to identify receptor molecules that control key aspects of insect behavior and discovering compounds that block or activate the function of these receptors and to identify new compounds that may have use in agricultural crop protection and insect-borne disease management such as agents that completely block the insect sense of smell rendering an individual or a field invisible to insects. Other potential products include new and effective insect repellants and novel potent attractants for use in insect bait stations and traps.
We believe the applications offering the greatest potential for developing products in the intermediate term are for mosquito repellants to be sold by household product companies. Other potential markets for our olfaction intellectual property include:

 
 
food production;
 
agricultural chemical companies; and
 
pharmaceutical companies.

Our executive officer and Board of Directors are also seeking opportunities with non-profit agencies and with potential commercial partners to leverage our olfaction intellectual property for the development of control agents for biting insects, in particular, insect vectors of malaria and other diseases.

_______________________________________________________________________________________________________________________________________________________________________________________

Found at Bill Gates website, posted 10/26/10 smile

"Similarly, Richard Axel, a Nobel Prize-winning neuroscientist, and Leslie Vosshall, a scientist at The Rockefeller University, are now collaborating with Bayer CropSciences and SentiSearch to continue their research on novel compounds that block insects' abilities to find plant or human targets. The compounds they identify could become the insect repellent of the future."

The whole article:
http://www.thegatesnotes.com/Thinking/article.aspx?id=177

_______________________________________________________________________________________________________________________________________________________________________________________

OTC Market Tier
Pink Quote/OTCBB
Primary SIC - Industry Classification
6794 - Patent owners and lessors
State Of Incorporation
DE
Jurisdiction Of Incorporation
United States
Company Officers
Joseph K. Pagano, Chairman, CEO, Treasurer, Secretary
Frederick R. Adler, Dir.
Dean Gresk, Dir.
SEC Reporting Company
CIK 0001380024

SSRC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#162   It would be interesting to know if there’s e-ore 05/05/20 08:41:50 PM
#161   What bothers me is that is active in dontknowsht 05/05/20 07:56:43 PM
#160   It was owned by some wealthy people who e-ore 05/05/20 07:54:05 PM
#159   interesting. seems like no one is on it dontknowsht 05/05/20 07:48:46 PM
#158   No idea. I've been out of this one e-ore 05/05/20 07:22:47 PM
#157   ??? 77% on 89k shares end of day? dontknowsht 05/05/20 07:00:05 PM
#156   something happening here? noticed the end of day volume. dontknowsht 05/05/20 06:58:07 PM
#155   $SSRC: I don't know about you.... Butttttttttttttttt makinezmoney 09/26/19 10:09:51 AM
#154   Definitely an all or nothing play. The new e-ore 01/25/12 01:20:26 PM
#153   Very interesting situation. Am watching.... satelliteguy 01/25/12 01:03:00 PM
#152   Form 4 filed by the CEO today. Like e-ore 12/28/11 02:55:58 PM
#151   10q for 9/30/11 filed today. In it, the e-ore 11/14/11 03:25:10 PM
#150   Dr. Axel spoke at the "embomeeting" last month. e-ore 10/05/11 06:28:49 PM
#149   Ibox updated 10/4/11 with new (New York City) e-ore 10/04/11 08:14:19 AM
#148   This, from the SSRC website, is a great e-ore 10/04/11 07:53:03 AM
#147   From the last SSRC 10k: e-ore 09/20/11 03:44:51 PM
#146   An interesting pr on the Bayer Crop Science e-ore 09/15/11 08:50:52 AM
#145   Here's an opinion on the Gates Foundation grants. e-ore 09/09/11 10:22:46 PM
#144   It's been very quiet, but Bayer still mentioning e-ore 09/09/11 09:46:21 PM
#143   SSRC - Raised A/S to 40,000,000 from 20,000,000 e-ore 08/10/11 04:40:57 PM
#142   For you scientists out there. This is SSRC's e-ore 07/14/11 07:31:06 AM
#141   A nice description of SSRC e-ore 07/14/11 07:24:11 AM
#140   Two filings today. A DEF 14A proxy statement, e-ore 06/28/11 04:43:09 PM
#139   PRE 14A filed yesterday, 6/19/11. They're looking to e-ore 06/10/11 03:04:21 PM
#138   10q out today. Nothing new in it, except e-ore 05/16/11 05:22:09 PM
#137   From the World Health Organization "REPORT OF THE e-ore 05/03/11 05:04:14 PM
#136   From Bayer Crop Science homepage. Click on "April e-ore 04/23/11 12:55:01 PM
#134   SSRC Beneficial ownership 75.5% as listed in the e-ore 04/23/11 09:00:05 AM
#133   From www.sentisearch.com e-ore 04/23/11 08:36:05 AM
#132   Very happy that Bayer Crop Science, one of e-ore 04/23/11 08:31:25 AM
#131   I thought about it; that's from the 2010 e-ore 04/20/11 01:44:45 PM
#130   I suppose you could shrink this to your TTT 04/20/11 01:43:01 PM
#129   From the SSRC website. e-ore 04/20/11 01:05:19 PM
#128   Wow, that's an awsome looking website. The future Money_Train 04/19/11 11:10:23 AM
#127   I wish there was a link to SSRC e-ore 04/18/11 09:40:20 PM
#126   It'll take me awhile to read this one over..:-) TTT 04/18/11 09:32:42 PM
#125   And very informative :) e-ore 04/18/11 09:30:27 PM
#124   WOW!!! Very nice, very professional!! TTT 04/18/11 09:21:14 PM
#123   WEEEEEEEEEEEEEE! We have a website! e-ore 04/18/11 09:07:15 PM
#122   Thanks e-ore for posting the 10K, and as Money_Train 03/31/11 06:35:44 PM
#121   The 2010 10K e-ore 03/31/11 05:24:37 PM
#120   SSRC 10K out today. Haven't read it all e-ore 03/31/11 04:30:59 PM
#119   We should see the 2010 10K this week e-ore 03/27/11 01:53:16 AM
#118   Maybe this is indicative of some progress? Dr e-ore 03/15/11 07:46:59 PM
#117   Good morning. I was a little surprised to e-ore 03/07/11 09:47:12 AM
#116   Great information e-ore thank you for posting…….. Money_Train 03/07/11 09:16:28 AM
#115   From the 2010 Bayer annual report, page 43. e-ore 03/06/11 12:10:04 PM
#114   New company description at businessweek.com e-ore 03/06/11 11:44:15 AM
#113   10q not due, the next filing will be e-ore 02/24/11 07:16:12 AM
#112   And confirmation that SSRC benefits from Dr. Axel's e-ore 02/12/11 10:31:33 PM
PostSubject
Consent Preferences